CYB704 not checked

Sandoz

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
7 active
7 in total · 7 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Relapsing Multiple Sclerosis
Main trialPhase 3
“The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R). The main questions it aims to answer are: * Is CYB704 distributed in the body in the same way as the reference product (demonstration of pharmacokinetic (PK) similarity)? * Does have CYB704 the same treatment effect and side effects as the reference product? Researchers will compare CYB704 to a Ocrevus (Ocrevus-US and Ocrevus-EU). Participants will: * Take drug CYB704 or Ocrevus (Ocrevus-US and Ocrevus-EU) *…”In the company’s words, NCT06847724 on ClinicalTrials.gov
Other names
Ocrelizumab

Other drugs for Relapsing Multiple Sclerosis

All 54 drugs for Relapsing Multiple Sclerosis

Coming up0

No dates coming up.

Changes1

Last 90 days

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 3 Nov 2026 Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Phase 3Authorised not given For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial
Phase 3Authorised not given Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS)
Phase 3/4Authorised not given Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis (BLOOMS): a randomized controlled trial
Phase 4Authorised not given The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
Phase 3Authorised not given STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years
Phase 3Authorised not given A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CYB704

Following is part of Solo: you see every change to CYB704 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in